Novogen Patent Covering Cantrixil, Trilexium Accepted in Australia

Novogen Limited

today announced that a patent application covering two of its key lead superbenzopyran (SBP) drug candidates has been accepted in Australia.  According to Novogen North America CEO, Dr Andrew Heaton, this patent application encompasses a suite of SBP compounds, including the two lead SBP drug candidates Cantrixil and Trilexium. The active ingredients in Cantrixil and Trilexium were discovered as part of Novogen's SBP discovery program. "Over the past 24 months, Novogen scientists have perfected the design and synthesis of extensive libraries of novel SBP's, using the Company's VAL-ID (Versatile Approach to Library based Iterative Design) approach," Dr Heaton said.  "Examination of the application proceeded smoothly with no substantive objections raised and the acceptance of this application by the Australian Patent Office represents a significant milestone in protecting our lead SBP assets," Dr Heaton said. "Critically the claims of the patent application are structured to cover the three key aspects of a drug patent: composition of matter, method of manufacture and treatment/medical